Extension analysis of a randomised trial in IDH-wild-type, TERT-mutant grade 2/3 glioma (58 patients: 18 RT, 40 CRT incl. 21 added non-randomly): temozolomide chemoradiotherapy vs RT alone was linked to median OS 25.8 vs 17.2 months (HR 0.31), with no grade ≥3 toxicity.
RCTn = 58
Zhang et al. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial